Skip to Main Content

++

Chapter 15: Breast Cancer

++
++
++

Select the agent that is administered via intramuscular injection for the treatment of metastatic estrogen receptor positive breast cancer.

++
++
++

a. Anastrozole

++
++

b. Arimidex

++
++

c. Herceptin

++
++

d. Faslodex

+
++

Answer d is correct. Faslodex is administered by IM injection to women with ER+ metastatic breast cancer.

++

Answer a in incorrect. Anastrozole is administered orally to patients with ER+ metastatic breast cancer.

++

Answer b is incorrect. Arimidex is administered orally to patients with breast cancer

++

Answer c is incorrect. Herceptin is administered intravenously to patients with breast cancer characterized by an overexpression of HER2.

++
++
++

Which of the following conditions would be a contraindication to administration of tamoxifen for the prevention of breast cancer in a “high-risk” premenopausal patient?

++
++
++

a. History of deep venous thrombosis

++
++

b. First-degree relative with ER negative breast cancer

++
++

c. History of diabetes mellitus

++
++

d. History of seizures

+
++

Answer a is correct. Tamoxifen is associated with an increased risk for developing thromboembolic events. Administration of tamoxifen to prevent breast cancer is contraindicated in patients with a history of deep venous thrombosis or pulmonary emboli.

++

Answer b is incorrect. The estrogen receptor status of first-degree relatives is not a contraindication to prescribing tamoxifen to reduce the risk for developing breast cancer.

++

Answer c is incorrect. Diabetes mellitus is not a contraindication to prescribing tamoxifen to reduce the risk for developing breast cancer.

++

Answer d is incorrect. A history of seizures is not a contraindication to prescribing tamoxifen to reduce the risk for developing breast cancer.

++
++
++

A premenopausal woman with ER negative, node positive breast cancer is starting doxorubicin and cyclophosphamide adjuvant treatment. What would you recommend to determine the severity of the most ­common toxicity associated with this treatment regimen?

++
++
++

a. An electrocardiogram

++
++

b. A complete blood count including platelets 1 week after administration of the chemotherapy

++
++

c. Serum bilirubin and aspartate transaminase

++
++

d. Urinalysis

+
++

Answer b is correct. Myelosuppression (neutropenia, thrombocytopenia) is the most common treatment related adverse effect associated with this adjuvant treatment regimen. Nearly 100% of patients receiving this treatment regimen will experience myelosuppression.

++

Answer a is incorrect. Although doxorubicin has been associated with cardiomyopathy that ...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.